Can an mRNA therapy supercharge the immune system against cancer?

NCT ID NCT07751042

Recruiting now Disease control Sponsor: Strand Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advanced solid tumors, such as melanoma or certain lung cancers. The goal is to see if the treatment is safe, tolerable, and shows signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STX-003, an mRNA therapy that produces IL-12 to stimulate the immune system, given alone or with pembrolizumab (Keytruda)
What this could lead to: If successful, this could offer a new treatment option for advanced solid tumors, potentially improving outcomes when combined with an existing immunotherapy.
What could go wrong: This is an early-stage trial, so safety and effectiveness are not yet proven. The therapy may cause side effects or may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.